Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 171

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 8
Chunk 171
---
,151 202720,755 20283,479 Undiscounted minimum rental commitments$52,580 Interest(3,820)Operating lease liabilities$48,760 We provided our landlord a security deposit of $2.9 million as security for our leases, which is included within other non-current assets on our condensed consolidated balance sheet.

10

In August 2021, we entered into a long-term sublease agreement for 13,000 square feet of the office space at 38 Sidney Street, Cambridge, Massachusetts, which expired on December 31, 2024. In April 2022, we entered into a long-term sublease agreement for 27,000 square feet of the office space at 64 Sidney Street, Cambridge, Massachusetts, which expired on April 30, 2025.In May 2023, we entered into a long-term sublease agreement for 7,407 square feet of office space on the first floor of 64 Sidney Street, Cambridge, Massachusetts, which expired on July 31, 2025. In July 2025, we entered into a long-term sublease agreement with a new tenant for the same space, which will begin in November 2025 with the term of the lease running through February 2028.We recorded operating sublease income of $0.5 million and $1.6 million for the three months ended June 30, 2025 and 2024, respectively, and $1.8 million and $3.2 million for the six months ended June 30, 2025 and 2024, respectively, in other income, net in the condensed consolidated statements of operations. We hold security deposits from our sublessee of approximately $0.1 million which is recorded within other non-current assets on our condensed consolidated balance sheet.As of June 30, 2025, the future minimum lease payments to be received under the long-term sublease agreements were as follows:(In thousands)Remaining 2025$31 Total$31 

7. Accrued Expenses

Accrued expenses consisted of the following:(In thousands)June 30,2025December 31, 2024Accrued compensation$15,323 $29,935 Accrued research and development costs13,065 10,548 Accrued professional fees3,153 4,316 Accrued other3,748 2,062 Total accrued expenses$35,289